Its possible that earlier associations between GLP-1s and pancreatic cancer and pancreatitis were confounded by the increased risk of these conditions in the baseline population of people living with type 2 diabetes who are prescribed these medications
Drugs Future
Here's how they compare: Semaglutide (GLP-1 agonist) Mechanism: Single-action GLP-1 receptor agonist FDA status: Approved for type 2 diabetes and chronic weight management Expected weight loss: 15-20% of body weight in clinical trials Administration: Once-weekly injection Best for: Patients starting their weight loss journey seeking proven, well-studied medication Tirzepatide (dual GIP/GLP-1 agonist) Mechanism: Targets both GIP and GLP-1 receptors for enhanced metabolic effect FDA status: Approved for type 2 diabetes and chronic weight management Expected weight loss: Up to 22% of body weight in clinical trials Administration: Once-weekly injection Best for: Patients seeking more aggressive fat loss with dual-action metabolic support Retatrutide (triple agonist, not yet available) Mechanism: Targets GLP-1, GIP, and glucagon receptors FDA status: Not FDA-approved

Compounded semaglutide injections are $189/mo month-to-month, or from $149/mo on the 6-month plan and are available to all Florida residents
Sculpt MD MedSpa in Livermore is one of the premier medical spas in the Tri-Valley area
Your PlexusDx report provides educational, personalized insights related to genetic predispositionssuch as genes tied to appetite regulation (FTO), insulin sensitivity (TCF7L2), and calcium/vitamin D transport (GC)to help explain why nutrient timing and nutrient density may matter for long-term success while using GLP-1 therapy